Allarity Therapeutics Q2 FY26 net loss widens to $3.41 million; comprehensive loss narrows to $3.67 millionPUBT·Aug 14 at 07:01 AMALLR+5.93%
Allarity Therapeutics secures CLIA certification for in-house DRP testing labPUBT·Jul 7 at 09:01 AMALLR+5.93%
Allarity Therapeutics wins key US patent for stenoparib DRP companion diagnostic through 2042PUBT·Jun 30 at 07:04 AMALLR+5.93%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jun 22 at 07:05 AMCRVO+3.83%CDT+4.15%
Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO gynecological cancers congressPUBT·Jun 22 at 07:11 AMALLR+5.93%
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm | ALLR Stock NewsStockTitan·May 7 at 11:45 PMALLR+5.93%ARKG+10.46%
Allarity Therapeutics says stenoparib Phase 3 API manufacturing on track for Q3 2026 completionTradingView·May 6 at 07:13 AMALLR+5.93%VHT+3.34%
Allarity Therapeutics shares are trading higher after the company announced that its active pharmaceutical ingredient manufacturing campaign for stenoparib is progressing in line with the planned timeline for completion, no later than Q3 of 2026, at its world-class contract development and manufacturing organization.benzinga_article·May 5 at 11:16 AMALLR+5.93%FBT+4.27%
Allarity Therapeutics wins USPTO notice of allowance for stenoparib DRP patent, exclusivity through 2039TradingView·Apr 28 at 07:13 AMALLR+5.93%XLV+3.51%
